Cargando…
FcRn inhibitors: a novel option for the treatment of myasthenia gravis
Myasthenia gravis is an acquired, humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscular junction. The intervention-mediated clearance of immunoglobulin G (IgG) was shown to be effective in controlling the...
Autores principales: | Zhu, Li-Na, Hou, Hai-Man, Wang, Sai, Zhang, Shuang, Wang, Ge-Ge, Guo, Zi-Yan, Wu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154512/ https://www.ncbi.nlm.nih.gov/pubmed/36751773 http://dx.doi.org/10.4103/1673-5374.363824 |
Ejemplares similares
-
FcRN receptor antagonists in the management of myasthenia gravis
por: Bhandari, Vinaya, et al.
Publicado: (2023) -
Characterization of the Rabbit Neonatal Fc Receptor (FcRn) and Analyzing the Immunophenotype of the Transgenic Rabbits That Overexpresses FcRn
por: Catunda Lemos, Ana Paula, et al.
Publicado: (2012) -
The Role of FcRn in Antigen Presentation
por: Baker, Kristi, et al.
Publicado: (2014) -
The Neonatal Fc Receptor (FcRn): A Misnomer?
por: Pyzik, Michal, et al.
Publicado: (2019) -
The neonatal Fc receptor in cancer FcRn in cancer
por: Cadena Castaneda, Diana, et al.
Publicado: (2020)